๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed or Refractory CD19+ B-cell Lymphoma

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites๐Ÿ“ Chicago๐Ÿ“ Evanston๐Ÿ“ Providence AvenCell Therapeutics, Inc. ยท Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites๐Ÿ“ Denver๐Ÿ“ Atlanta๐Ÿ“ Fairway Verismo Therapeutics ยท Tests: SynKIR-310 CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Autologous CAR19 T lymphocytes A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) NCT07072169Phase 11 site๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: ABO2203 Injection CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: CAR-T Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia NCT07133997Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD19/CD22-CAR T cells Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients NCT06343090NA1 site๐Ÿ“ Beijing Beijing GoBroad Hospital ยท Tests: CD19 CAR T-cell, CD22 CAR T cells, hematopoietic stem-cell transplantation Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites๐Ÿ“ Heidelberg๐Ÿ“ Heidelberg University Hospital Heidelberg ยท Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL NCT05963217Phase 11 site๐Ÿ“ Toronto University Health Network, Toronto ยท Tests: TBI-2001, Cyclophosphamide, Fludarabine Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT05633615Phase 295 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Fayetteville SWOG Cancer Research Network ยท Tests: Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia NCT06081478Phase 21 site๐Ÿ“ Beijing Beijing Tongren Hospital ยท Tests: CD19/CD22-bispecific CAR-T cells Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma NCT06830031Phase 11 site๐Ÿ“ Tianjin Shanghai Exuma Biotechnology Ltd. ยท Tests: C402-CD19-CAR Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma NCT07725406Phase 11 site๐Ÿ“ New York Weill Medical College of Cornell University ยท Tests: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapโ€ฆ Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma NCT05842707Phase 1, Phase 21 site๐Ÿ“ Shanghai Aibin Liang๏ผŒMD๏ผŒPh.D. ยท Tests: dualCAR-NK19/70 cell Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies NCT05705570Phase 11 site๐Ÿ“ Sรฃo Paulo Nelson Hamerschlak ยท Tests: Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on dayโ€ฆ A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) NCT06446128EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Cell Therapy Group Co.,Ltd ยท Tests: CD19/CD20/BCMA CAR T cells CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520Phase 1, Phase 21 site๐Ÿ“ Milwaukee Medical College of Wisconsin ยท Tests: 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma NCT07344818EARLY Phase 11 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CAR-T cell therapy Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL NCT05702853Phase 1, Phase 21 site๐Ÿ“ Charleston Medical University of South Carolina ยท Tests: Cyclophosphamide injection, Fludarabine Injection, CD19-CD34t metabolically programmed CAR transduced T-cells Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial NCT06326008Phase 11 site๐Ÿ“ Beijing Beijing GoBroad Hospital ยท Tests: Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL NCT06346912EARLY Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: CD19-BAFF Targeted CAR T-cells Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Denver Vironexis Biotherapeutics Inc. ยท Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173Phase 2, Phase 327 sites๐Ÿ“ Toronto๐Ÿ“ Copenhagen๐Ÿ“ Aarhus Nord Merck Sharp & Dohme LLC ยท Tests: MK-1045, Blinatumomab, Acetaminophen, Diphenhydramine, Dexamethasone Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site๐Ÿ“ Ann Arbor University of Michigan Rogel Cancer Center ยท Tests: Biospecimen Collection, Pomalidomide Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT07368270Phase 11 site๐Ÿ“ Suzhou Jiangsu Topcel-KH Pharmaceutical Co., Ltd. ยท Tests: Anti-PD1 armored CD19 CAR-T cells Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL NCT06104592Phase 21 site๐Ÿ“ Tampa H. Lee Moffitt Cancer Center and Research Institute ยท Tests: Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy